A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.
Contemp Clin Trials Commun
; 36: 101232, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-38058513
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article